DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Etrolizumab is an investigational drug.
There have been 12 clinical trials for Etrolizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Ulcer, Colitis, Ulcerative, and Colitis. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].
There are ten US patents protecting this investigational drug and one hundred and seven international patents.
Recent Clinical Trials for Etrolizumab
|A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease||Hoffmann-La Roche||Phase 1|
|A Study to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously (SC) by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)||Genentech, Inc.||Phase 1|
|A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants||Genentech, Inc.||Phase 1|
Top disease conditions for Etrolizumab
Top clinical trial sponsors for Etrolizumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Etrolizumab||Get Started Free||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Get Started Free|
|Etrolizumab||Get Started Free||Methods for diagnosing and treating inflammatory bowel disease||GENENTECH, INC. (South San Francisco, CA)||Get Started Free|
|Etrolizumab||Get Started Free||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Etrolizumab||Australia||AU2013220749||2032-02-15||Get Started Free|
|Etrolizumab||Brazil||BR112014019627||2032-02-15||Get Started Free|
|Etrolizumab||Canada||CA2862476||2032-02-15||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|